NCT06603285View on ClinicalTrials.gov

A Study to Observe the Safety, Tolerability, and Efficacy of Remodulin

Not yet recruitingOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

October 16, 2025

Primary Completion Date

May 31, 2029

Study Completion Date

December 31, 2029

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Treprostinil

sc/iv continuously

Sponsors

Lead Sponsor

Excelsior
All Listed Sponsors
lead

Excelsior

INDUSTRY

NCT06603285 - A Study to Observe the Safety, Tolerability, and Efficacy of Remodulin | Biotech Hunter | Biotech Hunter